Mahalingam, D., Halama, N., & Jäger, D. (2016). Anti-oxidized macrophage migration inhibitory factor (oxMIF) antibody imalumab (BAX69) in advanced solid tumors: Final results of first-in-human phase 1 study. Annals of oncology, 27, . https://doi.org/10.1093/annonc/mdw368.08
Chicago-Zitierstil (17. Ausg.)Mahalingam, Devalingam, Niels Halama, und Dirk Jäger. "Anti-oxidized Macrophage Migration Inhibitory Factor (oxMIF) Antibody Imalumab (BAX69) in Advanced Solid Tumors: Final Results of First-in-human Phase 1 Study." Annals of Oncology 27 (2016). https://doi.org/10.1093/annonc/mdw368.08.
MLA-Zitierstil (9. Ausg.)Mahalingam, Devalingam, et al. "Anti-oxidized Macrophage Migration Inhibitory Factor (oxMIF) Antibody Imalumab (BAX69) in Advanced Solid Tumors: Final Results of First-in-human Phase 1 Study." Annals of Oncology, vol. 27, 2016, https://doi.org/10.1093/annonc/mdw368.08.